CM Management’s Lantern Pharma LTRN Stock Holding History

CM Management’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.08M	Buy	500,000 +250,000	+100%	+$733K	1.32%	32
2026 Q1	$343K	Buy	250,000 +25,000	+11%	+$69.9K	0.29%	67
2025 Q4	$682K	Hold	225,000	–	–	0.57%	49
2025 Q3	$979K	Buy	225,000 +25,000	+13%	+$104K	0.82%	47
2025 Q2	$632K	Hold	200,000	–	–	0.58%	52
2025 Q1	$708K	Hold	200,000	–	–	0.71%	41
2024 Q4	$638K	Buy	200,000 +15,000	+8%	+$51.4K	0.57%	47
2024 Q3	$679K	Buy	185,000 +105,000	+131%	+$432K	0.54%	52
2024 Q2	$374K	Buy	80,000 +15,000	+23%	+$90.2K	0.34%	57
2024 Q1	$572K	Sell	65,000 -15,000	-19%	-$80.2K	0.48%	54
2023 Q4	$342K	Buy	80,000 +5,000	+7%	+$17.6K	0.28%	63
2023 Q3	$256K	Hold	75,000	–	–	0.27%	60
2023 Q2	$423K	Buy	75,000 +15,000	+25%	+$77.5K	0.41%	57
2023 Q1	$290K	Hold	60,000	–	–	0.34%	53
2022 Q4	$362K	Buy	60,000 +10,000	+20%	+$50.1K	0.43%	54
2022 Q3	$239K	Buy	50,000 +4,900	+11%	+$26.3K	0.27%	66
2022 Q2	$258K	Buy	45,100 +11,335	+34%	+$67.6K	0.27%	66
2022 Q1	$241K	Buy	+33,765	New	+$225K	0.2%	71
2021 Q1	–	Sell	-10,000	Closed	-$193K	–	92
2020 Q4	$193K	Buy	+10,000	New	+$173K	0.18%	77

Other funds holding LTRN

EAM

Empery Asset Management New York $86.5M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

CM Management's LTRN Position: Q2 2026 in Review

CM Management increased its Lantern Pharma (LTRN) stake by 100% in Q2 2026, buying an estimated $733K and bringing the position to 500,000 shares worth $2.08M. The position accounts for 1.32% of the portfolio, ranked #32.

CM Management first reported a position in LTRN in Q4 2020 and has held it in 19 quarters since. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

CM Management held 500,000 shares of Lantern Pharma worth $2.08M as of Q2 2026.
CM Management bought 250,000 Lantern Pharma shares in Q2 2026, an estimated $733K.
Lantern Pharma made up 1.32% of CM Management's portfolio in Q2 2026, its #32 holding.
CM Management first reported a position in Lantern Pharma in Q4 2020 and has held it in 19 quarters since.
39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on CM Management's 13F filing for Q2 2026, filed 13 Aug 2026.